Natco Pharma Ltd.

NSE: NATCOPHARM | BSE: 524816 | ISIN: INE987B01026 | Industry: Pharmaceuticals
| Value Stock, Under Radar
795.4000 -25.35 (-3.09%)
NSE Sep 29, 2025 15:31 PM
Volume: 727.8K
 

logo
Natco Pharma Ltd.
15 Feb 2019
795.40
-3.09%
Geojit BNP Paribas
EBITDA margin was down by 1200bps on account of lower margin realisation from Oseltamivir sales in the US (treatment for flu). Initiated work on green-field manufacturing facilities for producing niche agrichemicals with focus on formulation products. Launched Valsartan-Sacubitril tablet in India and filed ANDA for generic version of Ibrutinib tablets in the US . We revise downward our Revenue/PAT estimates by 4%/3% for FY20 to factor lower sales from the US....
Geojit BNP Paribas decreased Hold price target of Natco Pharma Ltd. to 940.0 on 17 Sep, 2025.
More from Natco Pharma Ltd.
Recommended